Vir Biotechnology: Hep B And Cancer Projects March On

Vir Biotechnology (NASDAQ: VIR ) is a stock I covered back in January after a meteoric rally in share price, and I came away with optimism despite the fact that there was serious risk associated withI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in t ...